Recipharm
Stockholm, Sweden
Program data pending ClinicalTrials.gov matching
—
Not Assessed
○ FDA Inspections
○ Clinical Trials
○ SEC Filings
✓ Press (10)
○ EMA GMP
Signal Score & Pillar Breakdown
Quality Compliance
—
No FDA inspection records found. This CDMO may operate under a different legal name or may not have US FDA-inspected facilities.
FDA InspectionsNo US records on file
No FDA inspection records found for this manufacturer
Quality score requires FDA inspection data
Operations
—
No ClinicalTrials.gov facility matches confirmed for this manufacturer.
Programs
— no verified data
Sponsors— no verified data
ModalitiesOral Solid Dose (OSD), Sterile Fill-Finish, Injectables, Blow-Fill-Seal (BFS), Semi-Solids, Liquids, Biologics, HPAPI, Beta-Lactams
No clinical trial matches found for this manufacturer
Operational score requires ClinicalTrials.gov data
Data sourced from ClinicalTrials.gov, FDA, SEC EDGAR, and verified press only. No unverified estimates shown.
Financial Stability
—
Insufficient financial data. Score requires company profile or SEC filings.
SEC FilingsPrivate company
Private company
Financial assessment: 60.0/100
Capacity
—
Insufficient capacity data. Score requires company profile with manufacturing site information.
Recent Press10 articles
Broad modality coverage (9 modalities)
Recent News 10 articles
Recipharm focuses footprint with sale of Israel API plant, new CDMO partnership - Fierce Pharma
Recipharm sells manufacturing site to Scinai in biologics collaboration - European Pharmaceutical Review
Scinai Announces Completion of Acquisition of Recipharm Israel Ltd. and Strategic Commercial Collaboration with Recipharm - PR Newswire
Scinai Immunotherapeutics Buys Recipharm Israel - Contract Pharma
Scinai Immunotherapeutics Buys Recipharm Israel Unit, Seals Strategic CDMO Pact - TipRanks
Oxford taps CDMO Recipharm to handle additional manufacturing work in malaria vaccine collab - Fierce Pharma
Divestments see Recipharm zoning in on core CDMO offerings - BioProcess International
Recipharm expands manufacturing to meet demanding FDA requirements - The Pharma Letter
Responding to tougher FDA standards, Recipharm debuts new facility for beta-lactam drugs - Fierce Pharma
Recipharm Advanced Bio Partners with Infant Bacterial Therapeutics for Commercial Drug Production - Genetic Engineering and Biotechnology News
Represent this organization? Contact us to verify or update this profile.